Document:

WARRANT

THE SECURITIES REPRESENTED BY THIS WARRANT AND SECURITIES ISSUABLE UPON EXERCISE
OF THIS WARRANT HAVE BEEN ISSUED PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), AND HAVE NOT BEEN
REGISTERED UNDER THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS. THE
SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT AND APPLICABLE STATE SECURITIES
LAWS OR AN OPINION OF COUNSEL IN FORM REASONABLY ACCEPTABLE TO THE ISSUER THAT
REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT. ANY SUCH OFFER, SALE,
ASSIGNMENT OR TRANSFER MUST ALSO COMPLY WITH THE APPLICABLE STATE SECURITIES
LAWS.

                        Generex Biotechnology Corporation
                        WARRANT TO PURCHASE COMMON STOCK

Warrant No.: TSGIU-[Number]                          Number of Shares: [Shares]
Date of Original Issuance: May [Date], 2000

Generex Biotechnology Corporation, a Delaware corporation (the "Company"),
hereby certifies that, for Ten United States Dollars ($10.00) and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, [Name], the registered holder hereof or its permitted assigns, is
entitled, subject to the terms set forth below, to purchase from the Company
upon surrender of this Warrant, at any time or times on or after the date
hereof, but not after 11:59 P.M. Central Time on the Expiration Date (as defined
herein) [Amount] fully paid nonassessable shares of Common Stock (as defined
herein) of the Company (the "Warrant Shares") at the purchase price per share
provided in Section 1(b) below.

     Section 1.

     (a) Securities Purchase Agreement. This Warrant is one of a series of
Warrants (the "Warrants") issued pursuant to the terms of an Exclusive Finder's
Agreement dated May 9, 2000 (the "Finder's Agreement").

     (b) Definitions. The following words and terms as used in this Warrant
shall have the following meanings:

                                       1

<PAGE>

         (i) "Approved Stock Plan" shall mean any employee benefit plan as
defined in Rule 405 under the Securities Act which has been approved by the
Board of Directors of the Company, pursuant to which the Company's securities
may be issued to any employee, officer, director, consultant or other service
provider for services provided to the Company.

         (ii) "Common Stock" means (i) the Company's common stock, $.001 par
value per share, and (ii) any capital stock into which such Common Stock shall
have been changed or any capital stock resulting from a reclassification of such
Common Stock.

         (iii) "Common Stock Deemed Outstanding" means, at any given time, the
number of shares of Common Stock actually outstanding at such time, plus the
number of shares of Common Stock deemed to be outstanding pursuant to Sections
8(b)(i) and 8(b)(ii) hereof regardless of whether the Options (as defined below)
or Convertible Securities (as defined below) are actually exercisable or
convertible at such time, but excluding any shares of Common Stock owned or held
by or for the account of the Company or issuable upon exercise of the Warrants.

         (iv) "Convertible Securities" means any stock or securities (other than
Options) directly or indirectly convertible into or exchangeable for Common
Stock.

         (v) "Expiration Date" means May 17, 2005.

         (vi) "Options" means any rights, warrants or options to subscribe for
or purchase Common Stock or Convertible Securities.

         (vii) "Other Securities" means (i) the other Warrants, (ii) the shares
of Common Stock issued pursuant to the Securities Purchase Agreement, (iii)
securities purchased by Other Purchasers (as defined in the Securities Purchase
Agreement), and (iv) securities sold through LT&C under the Investment Banking
Agreement (as those terms are defined in the Securities Purchase Agreement).

         (viii) "Person" means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated
organization and a government or any department or agency thereof.

         (ix) "Principal Market" means the Nasdaq National Market or Nasdaq
Small-Cap Market.

         (x) "Securities Act" means the Securities Act of 1933, as amended.

         (xi) "Warrant" means this Warrant and all Warrants issued in exchange,
transfer or replacement of any thereof.

         (xii) "Warrant Exercise Price" shall be Ten ($10.00) Dollars per common
share, subject to adjustment as hereinafter provided.

                                       2

<PAGE>

     Section 2. Exercise of Warrant.

     (a) Subject to the terms and conditions hereof, this Warrant may be
exercised by the holder hereof then registered on the books of the Company, in
whole or in part, at any time on any business day on or after the opening of
business on the date hereof and prior to 11:59 P.M. Central Time on the
Expiration Date by (i) delivery of a written notice, in the form of the
subscription notice attached as Exhibit A hereto (the "Exercise Notice"), of
such holder's election to exercise this Warrant, which notice shall specify the
number of Warrant Shares to be purchased, (ii) (A) payment to the Company of an
amount equal to the Warrant Exercise Price multiplied by the number of Warrant
Shares as to which this Warrant is being exercised (plus any applicable issue or
transfer taxes) (the "Aggregate Exercise Price") in cash or by check or wire
transfer or (B) by notifying the Company that it should subtract from the number
of Warrant Shares issuable to the holder upon such exercise an amount of Warrant
Shares having a last reported sale price (as reported by Bloomberg) on the date
immediately preceding the date of the subscription notice equal to the Aggregate
Exercise Price of the Warrant Shares for which this Warrant is being exercised
(a "Cashless Exercise"), and (iii) the surrender to a common carrier for
delivery to the Company as soon as practicable following such date, this Warrant
(or an indemnification undertaking with respect to this Warrant in the case of
its loss, theft or destruction); provided, that if such Warrant Shares are to be
issued in any name other than that of the registered holder of this Warrant,
such issuance shall be deemed a transfer and the provisions of Section 7 shall
be applicable. In the event of any exercise of the rights represented by this
Warrant in compliance with this Section 2(a), a certificate or certificates for
the Warrant Shares so purchased, in such denominations as may be requested by
the holder hereof and registered in the name of, or as directed by, the holder,
shall be delivered at the Company's expense to, or as directed by, such holder
as soon as practicable, and in no event later than five (5) business days, after
the Company's receipt of the Exercise Notice, the Aggregate Exercise Price and
this Warrant (or an indemnification undertaking with respect to this Warrant in
the case of its loss, theft or destruction). Upon delivery of the Exercise
Notice and Aggregate Exercise Price referred to in clause (ii) (A) above or
notification to the Company of a Cashless Exercise referred to in clause (ii)
(B) above, the holder of this Warrant shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of this
Warrant as required by clause (iii) above or the certificates evidencing such
Warrant Shares. In the case of a dispute as to the determination of the Warrant
Exercise Price, the Company shall promptly issue to the holder the number of
shares of Common Stock that is not disputed and shall submit the disputed
determinations or arithmetic calculations to the holder via facsimile within
five (5) business days of receipt of the holder's subscription notice. If the
holder and the Company are unable to agree upon the determination of the Warrant
Exercise Price or arithmetic calculation of the Warrant Shares within five (5)
business days of such disputed determination or arithmetic calculation being
submitted to the holder, then the Company shall immediately submit via facsimile
(i) the disputed determination of the Warrant Exercise Price to an independent,
reputable investment banking firm or (ii) the disputed arithmetic calculation of
the Warrant Shares to its independent, outside accountant. The Company shall
cause the investment banking firm or the accountant, as the case may be, to
perform the determinations or calculations and notify the Company and the holder
of the results no later than forty-eight (48) hours from the time it receives
the disputed determinations or calculations. Such investment banking firm's or
accountant's determination or calculation, as the case may be, shall be deemed
conclusive absent manifest error and the Company shall be liable for the costs
and expenses related to such determination or calculation.

                                       3

<PAGE>

     (b) Unless the rights represented by this Warrant shall have expired or
shall have been fully exercised, the Company shall, as soon as practicable and
in no event later than five (5) business days after any exercise and at its own
expense, issue a new Warrant identical in all respects to this Warrant exercised
except it shall represent rights to purchase the number of Warrant Shares
purchasable immediately prior to such exercise under this Warrant exercised,
less the number of Warrant Shares with respect to which such Warrant is
exercised.

     (c) If the Company shall fail for any reason or for no reason to issue to
the holder on a timely basis as described in this Section 2, a certificate for
the number of shares of Common Stock to which the holder is entitled upon the
holder's exercise of this Warrant or a new Warrant for the number of shares of
Common Stock to which such holder is entitled pursuant to Section 2(b) hereof,
the Company shall, in addition to any other remedies under this Warrant or the
Securities Purchase Agreement or otherwise available to such holder, including
any indemnification under the Securities Purchase Agreement, pay as additional
damages in cash to such holder on each day the issuance of such Common Stock
certificate or new Warrant, as the case may be, is not timely effected an amount
equal to .25% of the product of (A) the sum of the number of shares of Common
Stock not issued to the holder on a timely basis and to which the holder is
entitled and/or, the number of shares represented by the portion of this Warrant
which is not being converted, as the case may be, and (B) the average of the
closing bid price of the Common Stock for the three consecutive trading days
immediately preceding the last possible date which the Company could have issued
such Common Stock or Warrant, as the case may be, to the holder without
violating this Section 2.

     (d) The Company shall not affect any exercise of any Warrant and no holder
of any Warrant shall have the right to exercise any Warrant pursuant to Section
2 to the extent that after giving effect to such exercise such Person (together
with such Person's affiliates) (A) would beneficially own in excess of 4.9% of
the outstanding shares of the Common Stock following such conversion and (B)
would have acquired, through exercise of any Warrant or otherwise, in excess of
4.9% of the outstanding shares of the Common Stock following such exercise
during the 60-day period ending on and including such exercise date. For
purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by a Person and its affiliates or acquired by a Person and
its affiliates, as the case may be, shall include the number of shares of Common
Stock issuable upon exercise of the Warrants with respect to which the
determination of such sentence is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the
remaining, nonexercisable Warrants beneficially owned by such Person and its
affiliates and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially
owned by such Person and its affiliates. Except as set forth in the preceding
sentence, for purposes of this Section 2(d), beneficial ownership shall be
calculated in accordance with Section 13(d) of the Securities Exchange Act of
1934, as amended. Notwithstanding anything to the contrary contained herein,
each Exercise Notice shall constitute a representation by the holder submitting
such Exercise Notice that, after giving effect to such Exercise Notice, (A) the
holder will not beneficially own (as determined in accordance with this Section
2(d)) and (B) during the 60-day period ending on and including such exercise
date, the holder will not have acquired, through exercise of any Warrant or
otherwise, a number of shares of Common Stock in excess of 4.9% of the
outstanding shares of Common Stock as reflected in the Company's most recent
Form 10-Q or Form 10-K, as the case may be, or more recent public press release
or other

                                       4

<PAGE>

public notice by the Company setting forth the number of shares of Common Stock
outstanding, but after giving effect to exercise of any Warrant by such holder
since the date as of which such number of outstanding shares of Common Stock was
reported.

     Section 3. Covenants as to Common Stock. The Company hereby covenants and
agrees as follows:

     (a) This Warrant is, and any Warrant issued in substitution for or
replacement of this Warrant will upon issuance be, duly authorized and validly
issued.

     (b) All Warrant Shares which may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be validly issued, fully paid
and nonassessable and free from all taxes, liens and charges with respect to the
issue thereof.

     (c) During the period within which the rights represented by this Warrant
may be exercised, the Company will at all times have authorized and reserved at
least 100% of the number of shares of Common Stock needed to provide for the
exercise of the rights then represented by this Warrant and the par value of
said shares will at all times be less than or equal to the applicable Warrant
Exercise Price.

     (d) The Company shall promptly secure the listing of the shares of Common
Stock issuable upon exercise of this Warrant upon each national securities
exchange or automated quotation system, if any, upon which shares of Common
Stock are then listed (subject to official notice of issuance upon exercise of
this Warrant) and shall maintain, so long as any other shares of Common Stock
shall be so listed, such listing of all shares of Common Stock from time to time
issuable upon the exercise of this Warrant; and the Company shall so list on
each national securities exchange or automated quotation system, as the case may
be, and shall maintain such listing of, any other shares of capital stock of the
Company issuable upon the exercise of this Warrant if and so long as any shares
of the same class shall be listed on such national securities exchange or
automated quotation system.

     (e) The Company will not, by amendment of its Certificate of Incorporation
or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities, or any other voluntary action, avoid
or seek to avoid the observance or performance of any of the terms to be
observed or performed by it hereunder, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may reasonably be requested by the holder of this
Warrant in order to protect the exercise privilege of the holder of this Warrant
against dilution or other impairment, consistent with the tenor and purpose of
this Warrant will take all such actions as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon the exercise of this Warrant.

     (f) This Warrant will be binding upon any entity succeeding to the Company
by merger, consolidation or acquisition of all or substantially all of the
Company's assets.

     Section 4. Taxes. The Company shall pay any and all taxes which may be
payable with respect to the issuance and delivery of Warrant Shares upon
exercise of this Warrant.

                                       5

<PAGE>

     Section 5. Warrant Holder Not Deemed a Stockholder. Except as otherwise
specifically provided herein, no holder, as such, of this Warrant shall be
entitled to vote or receive dividends or be deemed the holder of shares of the
Company for any purpose, nor shall anything contained in this Warrant be
construed to confer upon the holder hereof, as such, any of the rights of a
stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification
of stock, consolidation, merger, conveyance or otherwise), receive notice of
meetings, receive dividends or subscription rights, or otherwise, prior to the
issuance to the holder of this Warrant of the Warrant Shares which he or she is
then entitled to receive upon the due exercise of this Warrant. In addition,
nothing contained in this Warrant shall be construed as imposing any liabilities
on such holder to purchase any securities (upon exercise of this Warrant or
otherwise) or as a stockholder of the Company, whether such liabilities are
asserted by the Company or by creditors of the Company. Notwithstanding this
Section 5, the Company will provide the holder of this Warrant with copies of
the same notices and other information given to the stockholders of the Company
generally, contemporaneously with the giving thereof to the stockholders.

     Section 6. Representations of Holder. The holder of this Warrant, by the
acceptance hereof, represents that it is acquiring this Warrant and the Warrant
Shares for its own account for investment only and not with a view towards, or
for resale in connection with, the public sale or distribution of this Warrant
or the Warrant Shares, except pursuant to sales registered or exempted under the
Securities Act; provided, however, that by making the representations herein,
the holder does not agree to hold this Warrant or any of the Warrant Shares for
any minimum or other specific term and reserves the right to dispose of this
Warrant and the Warrant Shares at any time in accordance with or pursuant to a
registration statement or an exemption under the Securities Act. The holder of
this Warrant further represents, by acceptance hereof, that, as of this date,
such holder is an "accredited investor" as such term is defined in Rule
501(a)(1) of Regulation D promulgated by the Securities and Exchange Commission
under the Securities Act (an "Accredited Investor").

     Section 7. Ownership and Transfer.

     (a) The Company shall maintain at its principal executive offices (or such
other office or agency of the Company as it may designate by notice to the
holder hereof), a register for this Warrant, in which the Company shall record
the name and address of the person in whose name this Warrant has been issued,
as well as the name and address of each transferee. The Company may treat the
person in whose name any Warrant is registered on the register as the owner and
holder thereof for all purposes, notwithstanding any notice to the contrary, but
in all events recognizing any transfers made in accordance with the terms of
this Warrant.

     (b) This Warrant and the rights granted to the holder hereof are
transferable, in whole or in part, upon surrender of this Warrant, together with
a properly executed warrant power in the form of Exhibit B attached hereto;
provided, however, that any transfer or assignment shall be subject to the
conditions set forth in Section 7(c) below.

     (c) The holder of this Warrant understands that this Warrant has not been
and is not expected to be, registered under the Securities Act or any state
securities laws, and may not be offered for sale, sold, assigned or transferred
unless (i) subsequently registered thereunder, or (ii) the

                                       6

<PAGE>

transferee is an affiliated entity that is an Accredited Investor, or (iii) such
holder shall have delivered to the Company an opinion of counsel, in generally
acceptable form, to the effect that the securities to be sold, assigned or
transferred may be sold, assigned or transferred pursuant to Regulation S under
the Securities Act or to an exemption from such registration; provided that (A)
any sale of such securities made in reliance on Rule 144 promulgated under the
Securities Act may be made only in accordance with the terms of said Rule and
further, if said Rule is not applicable, any resale of such securities under
circumstances in which the seller (or the person through whom the sale is made)
may be deemed to be an underwriter (as that term is defined in the Securities
Act) may require compliance with some other exemption under the Securities Act
or the rules and regulations of the Securities and Exchange Commission
thereunder; and (B) neither the Company nor any other person is under any
obligation to register the Warrants under the Securities Act or any state
securities laws or to comply with the terms and conditions of any exemption
thereunder.

     Section 8. Adjustment of Warrant Exercise Price and Number of Shares. The
Warrant Exercise Price and the number of shares of Common Stock issuable upon
exercise of this Warrant shall be adjusted from time to time as follows:

     (a) Adjustment of Warrant Exercise Price and Number of Shares upon Issuance
of Common Stock. Except for Company Common Stock issued upon exercise or
conversion of securities issued or contractual rights binding on the Company
outstanding prior to the Closing Date, if and whenever on or after the date of
issuance of this Warrant, the Company issues or sells, or in accordance with
Section 8(b) is deemed to have issued or sold, any shares of Common Stock
(including the issuance or sale of shares of Common Stock owned or held by or
for the account of the Company, but excluding Other Securities or shares of
Common Stock deemed to have been issued by the Company in connection with an
Approved Stock Plan or upon exercise or conversion of the Other Securities) for
a consideration per share less than the Warrant Exercise Price in effect
immediately prior to such time (the "Applicable Price"), then immediately after
such issue or sale the Warrant Exercise Price then in effect shall be reduced to
an amount equal to the product of (x) the Warrant Exercise Price in effect
immediately prior to such issue or sale and (y) the quotient determined by
dividing (1) the sum of (I) the product derived by multiplying the Applicable
Price by the number of shares of Common Stock Deemed Outstanding immediately
prior to such issue or sale, plus (II) the consideration, if any, received by
the Company upon such issue or sale, by (2) the product derived by multiplying
the (I) Applicable Price by (II) the number of shares of Common Stock Deemed
Outstanding immediately after such issue or sale. Upon each such adjustment of
the Warrant Exercise Price hereunder, the number of shares of Common Stock
acquirable upon exercise of this Warrant shall be adjusted to the number of
shares determined by multiplying the Warrant Exercise Price in effect
immediately prior to such adjustment by the number of shares of Common Stock
acquirable upon exercise of this Warrant immediately prior to such adjustment
and dividing the product thereof by the Warrant Exercise Price resulting from
such adjustment.

     (b) Effect on Warrant Exercise Price of Certain Events. For purposes of
determining the adjusted Warrant Exercise Price under Section 8(a) above, the
following shall be applicable:

         (i) Issuance of Options. If the Company in any manner grants any
Options and the lowest price per share for which one share of Common Stock is
issuable upon the

                                       7

<PAGE>

exercise of any such Option or upon conversion or exchange of any Convertible
Securities issuable upon exercise of any such Option is less than the Applicable
Price, then such share of Common Stock shall be deemed to be outstanding and to
have been issued and sold by the Company at the time of the granting or sale of
such Option for such price per share. For purposes of this Section 8(b)(i), the
"lowest price per share for which one share of Common Stock is issuable upon
exercise of such Options or upon conversion or exchange of such Convertible
Securities" shall be equal to the sum of the lowest amounts of consideration (if
any) received or receivable by the Company with respect to any one share of
Common Stock upon the granting or sale of the Option, upon exercise of the
Option and upon conversion or exchange of any Convertible Security issuable upon
exercise of such Option. No further adjustment of the Warrant Exercise Price
shall be made upon the actual issuance of such Common Stock or of such
Convertible Securities upon the exercise of such Options or upon the actual
issuance of such Common Stock upon conversion or exchange of such Convertible
Securities. Notwithstanding the foregoing, no adjustment shall be made pursuant
to this Section 8(b)(i) to the extent that such adjustment is based solely on
the fact that the Convertible Securities issuable upon exercise of such Option
are convertible into or exchangeable for Common Stock at a price which varies
with the market price of the Common Stock.

         (ii) Issuance of Convertible Securities. If the Company in any manner
issues or sells any Convertible Securities and the lowest price per share for
which one share of Common Stock is issuable upon such conversion or exchange
thereof is less than the Applicable Price, then such share of Common Stock shall
be deemed to be outstanding and to have been issued and sold by the Company at
the time of the issuance or sale of such Convertible Securities for such price
per share. For the purposes of this Section 8(b)(ii), the "lowest price per
share for which one share of Common Stock is issuable upon such conversion or
exchange" shall be equal to the sum of the lowest amounts of consideration (if
any) received or receivable by the Company with respect to one share of Common
Stock upon the issuance or sale of the Convertible Security and upon conversion
or exchange of such Convertible Security. No further adjustment of the Warrant
Exercise Price shall be made upon the actual issuance of such Common Stock upon
conversion or exchange of such Convertible Securities, and if any such issue or
sale of such Convertible Securities is made upon exercise of any Options for
which adjustment of the Warrant Exercise Price had been or are to be made
pursuant to other provisions of this Section 8(b), no further adjustment of the
Warrant Exercise Price shall be made by reason of such issue or sale.
Notwithstanding the foregoing, no adjustment shall be made pursuant to this
Section 8(b)(ii) to the extent that such adjustment is based solely on the fact
that such Convertible Securities are convertible into or exchangeable for Common
Stock at a price which varies with the market price of the Common Stock.

         (iii) Change in Option Price or Rate of Conversion. If the purchase
price provided for in any Options, the additional consideration, if any, payable
upon the issue, conversion or exchange of any Convertible Securities, or the
rate at which any Convertible Securities are convertible into or exchangeable
for Common Stock changes at any time, the Warrant Exercise Price in effect at
the time of such change shall be adjusted to the Warrant Exercise Price which
would have been in effect at such time had such Options or Convertible
Securities provided for such changed purchase price, additional consideration or
changed conversion rate, as the case may be, at the time initially granted,
issued or sold and the number of shares of Common Stock acquirable hereunder
shall be correspondingly readjusted. For purposes of this Section 8(b)(iii), if
the terms of any Option or Convertible Security that was outstanding as of the
date of issuance of this Warrant are changed in the manner described in the
immediately preceding sentence, then such Option or

                                       8

<PAGE>

Convertible Security and the Common Stock deemed issuable upon exercise,
conversion or exchange thereof shall be deemed to have been issued as of the
date of such change. No adjustment shall be made if such adjustment would result
in an increase of the Warrant Exercise Price then in effect.

     (c) Effect on Warrant Exercise Price of Certain Events. For purposes of
determining the adjusted Warrant Exercise Price under Sections 8(a) and 8(b),
the following shall be applicable:

         (i) Calculation of Consideration Received. In case any Option is issued
in connection with the issue or sale of other securities of the Company,
together comprising one integrated transaction in which no specific
consideration is allocated to such Options by the parties thereto, the Options
will be deemed to have been issued for a consideration of $.01. If any Common
Stock, Options or Convertible Securities are issued or sold or deemed to have
been issued or sold for cash, the consideration received therefor will be deemed
to be the net amount received by the Company therefor. If any Common Stock,
Options or Convertible Securities are issued or sold for a consideration other
than cash, the amount of such consideration received by the Company will be the
fair value of such consideration, except where such consideration consists of
publicly-traded securities, in which case the amount of consideration received
by the Company will be the market price of such securities for the twenty (20)
consecutive trading days immediately preceding the date of receipt. If any
Common Stock, Options or Convertible Securities are issued to the owners of the
non-surviving entity in connection with any merger in which the Company is the
surviving entity, the amount of consideration therefor will be deemed to be the
fair value of such portion of the net assets and business of the non-surviving
entity as is attributable to such Common Stock, Options or Convertible
Securities, as the case may be. The fair value of any consideration other than
cash or publicly-held securities will be determined jointly by the Company and
the holders of Warrants representing a majority of the shares of Common Stock
obtainable upon exercise of the Warrants then outstanding. If such parties are
unable to reach agreement within ten (10) days after the occurrence of an event
requiring valuation (the "Valuation Event"), the fair value of such
consideration will be determined within five business days after the tenth
(10th) day following the Valuation Event by an independent, reputable appraiser
jointly selected by the Company and the holders of Warrants representing a
majority of the shares of Common Stock obtainable upon exercise of the Warrants
then outstanding. The determination of such appraiser shall be final and binding
upon all parties and the fees and expenses of such appraiser shall be borne by
the Company.

         (ii) Record Date. If the Company takes a record of the holders of
Common Stock for the purpose of entitling them (1) to receive a dividend or
other distribution payable in Common Stock, Options or in Convertible Securities
or (2) to subscribe for or purchase Common Stock, Options or Convertible
Securities, then such record date will be deemed to be the date of the issue or
sale of the shares of Common Stock deemed to have been issued or sold upon the
declaration of such dividend or the making of such other distribution or the
date of the granting of such right of subscription or purchase, as the case
may be.

     (d) Adjustment of Warrant Exercise Price upon Subdivision or Combination of
Common Stock. If the Company at any time after the date of issuance of this
Warrant subdivides (by any stock split, stock dividend, recapitalization or
otherwise) one or more classes of its outstanding shares of Common Stock into a
greater number of shares, the Warrant Exercise Price in effect immediately prior
to such subdivision will be proportionately reduced and the number of shares of
Common Stock obtainable upon exercise of this Warrant will be proportionately
increased. If the

                                       9

<PAGE>

Company at any time after the date of issuance of this Warrant combines (by
combination, reverse stock split or otherwise) one or more classes of its
outstanding shares of Common Stock into a smaller number of shares, the Warrant
Exercise Price in effect immediately prior to such combination will be
proportionately increased and the number of shares of Common Stock obtainable
upon exercise of this Warrant will be proportionately decreased.

     (e) Distribution of Assets. If the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets)
to holders of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate
rearrangement or other transaction) (a "Distribution"), at any time after the
issuance of this Warrant, then, in each such case:

         (i) the Warrant Exercise Price in effect immediately prior to the close
of business on the record date fixed for the determination of holders of Common
Stock entitled to receive the Distribution shall be reduced, effective as of the
close of business on such record date, to a price determined by multiplying such
Warrant Exercise Price by a fraction of which (A) the numerator shall be the
Closing bid price on the trading day immediately preceding such record date
minus the value of the Distribution (as determined in good faith by the
Company's Board of Directors) applicable to one share of Common Stock, and (B)
the denominator shall be the Closing bid price on the trading day immediately
preceding such record date; and

         (ii) either (A) the number of Warrant Shares obtainable upon exercise
of this Warrant shall be increased to a number of shares equal to the number of
shares of Common Stock obtainable immediately prior to the close of business on
the record date fixed for the determination of holders of Common Stock entitled
to receive the Distribution multiplied by the reciprocal of the fraction set
forth in the immediately preceding clause (i), or (B) in the event that the
Distribution is of common stock of a company whose common stock is traded on a
national securities exchange or a national automated quotation system, then the
holder of this Warrant shall receive an additional warrant to purchase Common
Stock, the terms of which shall be identical to those of this Warrant, except
that such warrant shall be exercisable into the amount of the assets that would
have been payable to the holder of this Warrant pursuant to the Distribution had
the holder exercised this Warrant immediately prior to such record date and with
an exercise price equal to the amount by which the exercise price of this
Warrant was decreased with respect to the Distribution pursuant to the terms of
the immediately preceding clause (i).

     (f) Certain Events. If any event occurs of the type contemplated by the
provisions of this Section 8 but not expressly provided for by such provisions
(including, without limitation, the granting of stock appreciation rights,
phantom stock rights or other rights with equity features), then the Company's
Board of Directors will make an appropriate adjustment in the Warrant Exercise
Price and the number of shares of Common Stock obtainable upon exercise of this
Warrant so as to protect the rights of the holders of the Warrants; provided
that no such adjustment will increase the Warrant Exercise Price or decrease the
number of shares of Common Stock obtainable as otherwise determined pursuant to
this Section 8.

                                       10

<PAGE>

     (g) Notices.

         (i) Immediately upon any adjustment of the Warrant Exercise Price, the
Company will give written notice thereof to the holder of this Warrant, setting
forth in reasonable detail, and certifying, the calculation of such adjustment.

         (ii) The Company will give written notice to the holder of this Warrant
at least twenty (20) days prior to the date on which the Company closes its
books or takes a record (A) with respect to any dividend or distribution upon
the Common Stock, (B) with respect to any pro rata subscription offer to holders
of Common Stock or (C) for determining rights to vote with respect to any
Organic Change (as defined below), dissolution or liquidation, provided that
such information shall be made known to the public prior to or in conjunction
with such notice being provided to such holder.

         (iii) The Company will also give written notice to the holder of this
Warrant at least twenty (20) days prior to the date on which any Organic Change,
dissolution or liquidation will take place, provided that such information shall
be made known to the public prior to or in conjunction with such notice being
provided to such holder.

     Section 9. Purchase Rights; Reorganization, Reclassification,
Consolidation, Merger or Sale. (a) In addition to any adjustments pursuant to
Section 8 above, if at any time the Company grants, issues or sells any Options,
Convertible Securities or rights to purchase stock, warrants, securities or
other property pro rata to the record holders of any class of Common Stock (the
"Purchase Rights"), then the holder of this Warrant will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights
which such holder could have acquired if such holder had held the number of
shares of Common Stock acquirable upon complete exercise of this Warrant
immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of
which the record holders of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights.

     (b) Any recapitalization, reorganization, reclassification, consolidation,
merger, sale of all or substantially all of the Company's assets to another
Person or other transaction which is effected in such a way that holders of
Common Stock are entitled to receive (either directly or upon subsequent
liquidation) stock, securities or assets with respect to or in exchange for
Common Stock is referred to herein as "Organic Change." Prior to the
consummation of any (i) sale of all or substantially all of the Company's assets
to an acquiring Person or (ii) other Organic Change following which the Company
is not a surviving entity, the Company will secure from the Person purchasing
such assets or the successor resulting from such Organic Change (in each case,
the "Acquiring Entity") written agreement (in form and substance satisfactory to
the holders of Warrants representing a majority of the shares of Common Stock
obtainable upon exercise of the Warrants then outstanding) to deliver to each
holder of Warrants in exchange for such Warrants, a security of the Acquiring
Entity evidenced by a written instrument substantially similar in form and
substance to this Warrant and satisfactory to the holders of the Warrants
(including, an adjusted warrant exercise price equal to the value for the Common
Stock reflected by the terms of such consolidation, merger or sale, and
exercisable for a corresponding number of shares of Common Stock acquirable and
receivable upon exercise of the Warrants, if the value so reflected is less than
the Warrant Exercise Price in effect immediately prior to such consolidation,
merger or sale). Prior

                                       11

<PAGE>

to the consummation of any other Organic Change, the Company shall make
appropriate provision (in form and substance satisfactory to the holders of
Warrants representing a majority of the shares of Common Stock obtainable upon
exercise of the Warrants then outstanding) to insure that each of the holders of
the Warrants will thereafter have the right to acquire and receive in lieu of or
in addition to (as the case may be) the shares of Common Stock immediately
theretofore acquirable and receivable upon the exercise of such holder's
Warrants, such shares of stock, securities or assets that would have been issued
or payable in such Organic Change with respect to or in exchange for the number
of shares of Common Stock which would have been acquirable and receivable upon
the exercise of such holder's Warrant as of the date of such Organic Change
(without taking into account any limitations or restrictions on the
exercisability of this Warrant).

     Section 10. Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant
is lost, stolen, mutilated or destroyed, the Company shall, on receipt of an
indemnification undertaking, issue a new Warrant of like denomination and tenor
as this Warrant so lost, stolen, mutilated or destroyed.

     Section 11. Notice. Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Warrant must be in
writing and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one business day after deposit with
a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be as set forth below:

                  If to the Company:

                           Generex Biotechnology Corporation
                           33 Harbour Square, Suite 202
                           Toronto, Canada M5J 2G2
                           Telephone: (416) 364-2551
                           Facsimile: (416) 364-9363
                           Attention: E. Mark Perri

                  With copy to:

                           Eckert Seamans Cherin & Mellott
                           1515 Market Street, 9th Floor
                           Philadelphia, Pennsylvania 19102-1909
                           Telephone: (215) 851-8410
                           Facsimile: (215) 851-8383
                           Attention: Joseph Chicco, Esq.

     Or at such other address that the company shall specify by notice to the
holder; and:

     To a holder of this Warrant, at the address and facsimile number set forth
on the Finder's Agreement or at such other address and facsimile as shall be
delivered to the Company upon the issuance or transfer of this Warrant.

                                       12

<PAGE>

     Each party shall provide five days' prior written notice to the other party
of any change in address or facsimile number. Written confirmation of receipt
(A) given by the recipient of such notice, consent, waiver or other
communication, (B) mechanically or electronically generated by the sender's
facsimile machine containing the time, date, recipient facsimile number and an
image of the first page of such transmission or (C) provided by a nationally
recognized overnight delivery service shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from a nationally recognized overnight
delivery service in accordance with clause (i), (ii) or (iii) above,
respectively.

     Section 12. Amendments. This Warrant and any term hereof may be changed,
waived, discharged, or terminated only by an instrument in writing signed by the
party or holder hereof against which enforcement of such change, waiver,
discharge or termination is sought.

     Section 13. Date. This Warrant, in all events, shall be wholly void and of
no effect after the close of business on the Expiration Date, except that
notwithstanding any other provisions hereof, the provisions of Section 7 shall
continue in full force and effect after such date as to any Warrant Shares or
other securities issued upon the exercise of this Warrant.

     Section 14. Descriptive Headings; Governing Law. The descriptive headings
of the several Sections and paragraphs of this Warrant are inserted for
convenience only and do not constitute a part of this Warrant. This Warrant
shall be governed by the internal laws of the State of Illinois, without giving
effect to any choice of law or conflict of law provision or rule (whether of the
State of Illinois or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of Illinois.

     This Warrant has been duly executed by the Company this 31st day of
May, 2000.

                             GENEREX BIOTECHNOLOGY CORPORATION

                             By:
                                 -----------------------------------------------
                             Name:
                                   ---------------------------------------------
                             Title:
                                    --------------------------------------------

                                       13

<PAGE>

EXHIBIT A TO WARRANT
--------------------

                                SUBSCRIPTION FORM

        TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS WARRANT

     The undersigned holder hereby exercises the right to purchase
_________________ of the shares of Common Stock ("Warrant Shares") of Generex
Biotechnology Corporation, a Delaware corporation (the "Company"), evidenced by
the attached Warrant (the "Warrant"). Capitalized terms used herein and not
otherwise defined shall have the respective meanings set forth in the Warrant.

     1. Form of Warrant Exercise Price. The Holder intends that payment of the
Warrant Exercise Price shall be made as:

          a "Cash Exercise" with respect to _______________________
          Warrant Shares; and/or

          a "Cashless Exercise" with respect to ___________________
          Warrant Shares.

     2. Payment of Warrant Exercise Price. If the holder has elected a Cash
Exercise with respect to some or all of the Warrant Shares to be issued pursuant
hereto, the holder is transmitting herewith the sum of $___________________ to
the Company in payment for such Warrant Shares. If the holder has elected a
Cashless Exercise with respect to some or all of the Warrant Shares to be issued
pursuant hereto, the holder authorizes the Company to subtract from the number
of Warrant Shares otherwise issuable upon exercise of the Warrant an number of
warrant Shares determined in accordance with the terms of the Warrant, and the
Warrant shall be deemed cancelled as to that number of Warrant Shares.

     3. Delivery of Warrant Shares. The Company shall deliver to the holder
__________ Warrant Shares in accordance with the terms of the Warrant.

Date: ______________________ _________, 200__

Name of Registered Holder:

_____________________________________________

Signature:

By: _________________________________________

Print Name and Title: _______________________

Title: ______________________________________

                                       14

<PAGE>

                              EXHIBIT B TO WARRANT

                              FORM OF WARRANT POWER

FOR VALUE RECEIVED, the undersigned does hereby assign and transfer to
________________, Federal Identification No. __________, a warrant to purchase
____________ shares of the capital stock of Generex Biotechnology Corporation, a
Delaware corporation, represented by warrant certificate no. _____, standing in
the name of the undersigned on the books of said corporation. The undersigned
does hereby irrevocably constitute and appoint ______________, attorney to
transfer the warrants of said corporation, with full power of substitution in
the premises.

Dated: ________________, 200__

                             By:
                                 -----------------------------------------------
                             Name:
                                   ---------------------------------------------
                             Title:
                                    --------------------------------------------

                                       15<PAGE>

                              TERMINATION AGREEMENT
                                       and
                                     RELEASE
                                       and
                    AGREEMENT TO PROVIDE CONSULTING SERVICES
                                     between
                                LEONARD WASSERMAN
                                       and
                                TODAY'S MAN, INC.

         This Agreement ("Agreement") is made this 31st day of January 2000 by
and between Leonard Wasserman, residing at 191 Presidential Boulevard Apartment
#831, Bala Cynwyd, Pennsylvania 19004 ("Consultant" or "Wasserman") and Today's
Man, Inc., with an address at Moorestown West Corporate Center, 835 Lancer
Drive, Moorestown, New Jersey 08057 ("TM"). Wasserman and TM are each a party to
this Agreement and are collectively referred to hereunder as the "Parties".

         NOW, THEREFORE, in consideration of the promises, agreements and
undertakings set forth herein, and other good and valuable consideration which
the Parties deem adequate, and in addition, following Wasserman's separation
from TM as Executive Vice President, TM desires to retain Wasserman as an
independent contractor to consult on special projects and Wasserman desires to
serve in such capacity on the terms and conditions set forth herein, Wasserman
and TM each agree to be legally bound to all the terms and conditions set out in
this Agreement as follows:

         1.       Definitions. As used in this Agreement, any reference to TM
                  shall include its

<PAGE>

                  predecessors and successors, and all of its past, present and
                  future shareholders, directors, officers, employees (other
                  than Wasserman), representatives, attorneys, agents, assigns,
                  controlling corporations, affiliates and subsidiaries; and any
                  reference to Wasserman shall include his respective heirs,
                  administrators, representatives, executors, legatees,
                  successors, attorneys, agents and assigns.

         2.       Consulting Duties. Effective February 1, 2000, Wasserman will
                  cease his regular employment as Executive Vice President of
                  TM. For a period of twenty-one (21) months commencing February
                  1, 2000, Wasserman will, upon request of the Chairman of the
                  Board or CEO of TM, make himself available from time to time
                  to perform such consulting assignments as shall be mutually
                  agreed upon. Wasserman's consulting obligation to TM shall not
                  be deemed to preclude him from consulting with, or becoming
                  employed by, any other entity.

         3.       General Release.   Wasserman acknowledges that TM has met any
                  and all obligations arising from his prior relationships with
                  TM. Wasserman hereby releases and forever discharges TM of and
                  from any and all claims of any kind, whether or not now known,
                  which Wasserman ever had, now has or hereafter may have,
                  individually or in any other capacity, against TM relating to
                  anything that occurred before the signing of this agreement
                  arising out of his relationship with TM, and specifically
                  including all contract claims, including but not limited to,
                  claims under the severance pay plan, and all common law
                  claims, all claims under the Age Discrimination in Employment
                  Act, the Civil Rights Act of 1964, as amended, the New Jersey
                  Law Against

                                        2
<PAGE>

                  Discrimination, the New Jersey Conscientious Employee
                  Protection Act, the Pennsylvania Human Relations Act, Older
                  Workers Benefit Protection Act and any other federal, state or
                  local law or regulation. It is understood that this release
                  does not apply to any claim arising out of events occurring
                  after the date of this Agreement.

         4.       Employment Rights.  Wasserman expressly acknowledges that he
                  is aware of his legal right to consider this Agreement for a
                  period of twenty-one (21) days and that the Agreement will
                  remain open during this period. At the sole option of
                  Wasserman, this Agreement may be executed prior to the
                  expiration of this twenty-one (21) day period. TM hereby
                  advises Wasserman to consult with an attorney prior to
                  executing this Agreement. Wasserman acknowledges that he has
                  done so since being given this Agreement. Further, Wasserman
                  has the right to revoke this Agreement within seven (7) days
                  of the execution thereof. Wasserman expressly agrees that any
                  notice of revocation hereunder shall be in writing and shall
                  be deemed to have been duly given to TM if hand-delivered, or
                  if mailed, postage prepaid, by certified mail, return receipt
                  requested, within seven (7) days of the execution of this
                  Agreement to Mycal Webster, Human Resources Department,
                  Moorestown West Corporate Center, 835 Lancer Drive,
                  Moorestown, NJ 08057. The Agreement shall not become effective
                  until after such seven (7) day period has expired. Wasserman
                  understands that if he revokes this Agreement, he will not be
                  entitled to the monies provided for hereunder.

         5.       Proprietary Information.  At all times both during and after
                  this Agreement, Wasserman shall not, except with TM's express
                  prior written consent, directly

                                       3

<PAGE>

                  or indirectly, communicate, disclose or divulge to any
                  individual, sole proprietorship, joint venture, partnership,
                  corporation, association or any governmental or
                  non-governmental entity or authority (collectively "Person")
                  or use for his own benefit or the benefit of any Person, any
                  confidential or proprietary knowledge or information (no
                  matter when or how acquired), concerning the conduct and
                  detail of the business of TM.

         6.       Return of Property.

                  a.       Upon execution of this Agreement, Wasserman will
                           immediately return to TM all of its "Property."
                           "Property" means all assets, correspondence, files,
                           customer and prospects lists, other lists, price
                           books, catalogues, technical data, notes, memoranda,
                           drawings, papers, books, disks, computers and related
                           materials, tapes, documents and any other materials
                           which contain business, confidential and/or
                           proprietary information of TM. Property also means
                           all duplicates or copies thereof.

                  b.       Should Wasserman require any of TM's Property to
                           fulfil his obligations under this Agreement such
                           Property will be provided as determined by TM.

         7        Nature of Consulting Relationship. Wasserman shall perform his
                  consulting duties in his capacity as an independent contractor
                  and not an employee of TM. Wasserman shall be free to exercise
                  his discretion and independent judgment as to method and means
                  of performance of his services pursuant to this Agreement and
                  shall in no sense be considered to be an employee. Wasserman
                  will devote such business time and effort to the services set
                  forth

                                        4
<PAGE>

                  hereunder to fully, timely and properly complete all assigned
                  projects and tasks. Wasserman will perform on a best effort
                  basis and shall be provided with appropriate personnel and
                  equipment as to be agreed.

         8.       Non disparagement. Wasserman and TM both agree that they will
                  make no statements calculated or intended to be harmful or
                  derogatory concerning each of them or their respective
                  officers, agents, or employees, except as required under
                  subpoena or other governmental compulsion.

         9.       Non solicitation. Wasserman agrees that for the term of this
                  Agreement, he will not solicit or seek to persuade any
                  employee, consultant or independent contractor of TM to
                  discontinue his/her employment or relationship with TM, or to
                  become employed or engaged in any business directly or
                  indirectly competitive with TM.

         10.      Payment to Wasserman.

                  a.       In consideration for the promises, agreement and
                           undertakings set forth herein, TM agrees to pay
                           Wasserman Twenty-One Thousand, Six Hundred Forty-Two
                           Dollars and sixty-seven cents ($21,642.67) on
                           February 1, 2000 and on the first day of each
                           succeeding calendar month through and including
                           October 1, 2001.

                  b.       TM will also pay Wasserman health insurance premiums
                           at the same level of coverage on the date hereof
                           through October 31, 2001.

                  c.       In addition to any other remedies available to it,
                           upon receipt of competent evidence of any breach of
                           this Agreement by Wasserman, TM may cease payment
                           under this paragraph, provided it first notifies
                           Wasserman and affords an opportunity for discussion
                           and/or

                                        5

<PAGE>

                           remediation within thirty (30) days of such notice.

                  d.       If TM breaches this Agreement by missing any payment
                           required hereby (a payment which is not made within
                           seven (7) days of written notice from Wasserman to TM
                           - Attention CFO is a missed payment) then in his sole
                           discretion, Wasserman may:( i) sue to enforce the
                           terms of this Agreement; or (ii) pursue before the
                           appropriate Courts or Agencies any claims previously
                           waived in this Agreement. TM agrees not to plead any
                           statute of limitations as an affirmative defense in
                           the event of pursuing such claims.

         11.      Nature of Agreement.  It is understood and agreed by the
                  parties that this Agreement does not constitute an admission
                  of liability or wrongdoing on the part of TM; and that by
                  entering into this Agreement, TM does not admit that there has
                  been any unlawful or wrongful act whatsoever committed against
                  any party or person, which makes TM liable in any manner.
                  Except to the extent necessary to enforce the Agreement, it is
                  further agreed that neither this Agreement nor any part of it
                  is to be considered or used or admitted into evidence in any
                  proceeding of any character, judicial, administrative, or
                  otherwise. In the event this Agreement is not finally
                  consummated, it and any preceding discussions concerning the
                  proposed terms of this Agreement shall be without prejudice to
                  any party, and shall not be used in any subsequent proceeding,
                  judicial, administrative, or otherwise.

         12.      Entire Agreement.  This Agreement contains and constitutes the
                  entire understanding and agreement between the parties hereto
                  and supersedes and cancels all previous negotiations,
                  agreements, commitments, and writings in connection herewith.

                                        6

<PAGE>

                  Wasserman affirms that the only consideration for the signing
                  of this Agreement are the terms stated herein, and no other
                  promises or agreements of any kind have been made to or with
                  him by any person or entity whatsoever to cause him to sign
                  this Agreement, and that he fully understands the meaning and
                  intent of this Agreement.

         13.      Amendment.  This Agreement shall be binding upon Wasserman and
                  TM and may not be abandoned, supplemented, amended, changed,
                  or modified in any manner, orally or otherwise, except by an
                  instrument in writing of concurrent or subsequent date, signed
                  by Wasserman and a duly authorized representative of TM.

         14.      Construction. This Agreement shall be governed by and
                  construed in accordance with the laws of the State of
                  New Jersey.

                  The captions herein are inserted for convenience and do not
                  constitute a part of this Agreement and shall not be
                  admissible for the purposes of providing the intent of the
                  parties.

                  Wasserman states and represents that he has carefully read
                  this Agreement, that he has discussed it with his attorney,
                  understands the contents hereof, freely and voluntarily
                  assents to all the terms and conditions hereof, and signs the
                  same as his own free act. TM represents and warrants that this
                  Agreement is the duly authorized act of TM and that the
                  undersigned has the actual authority to execute this Agreement
                  on behalf of TM and bind it to the obligations set forth
                  herein.

           /s/ Leonard Wasserman                                    01/31/00
-----------------------------------------------------      ---------------------
               Leonard Wasserman                           Date

For Today's Man, Inc.

           /s/ Frank E. Johnson                                     01/31/00
-----------------------------------------------------      ---------------------
               Frank E. Johnson, EVP & CFO                 Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]